Jaguar Health, Inc. (JAGX)
| Market Cap | 11.29M |
| Revenue (ttm) | 11.30M |
| Net Income (ttm) | -41.67M |
| Shares Out | 19.11M |
| EPS (ttm) | -19.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,212 |
| Open | 0.580 |
| Previous Close | 0.595 |
| Day's Range | 0.580 - 0.598 |
| 52-Week Range | 0.460 - 28.500 |
| Beta | 1.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2023 |
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug in... [Read more]
Financial Performance
In 2022, Jaguar Health's revenue was $11.96 million, an increase of 175.80% compared to the previous year's $4.34 million. Losses were -$47.45 million, -9.77% less than in 2021.
Financial StatementsNews
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jagu...
Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined ...
Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%
Announces Focus on Four Cancers Common to Children & Canines for Upcoming Capitol Hill Briefing, Commitment to Advancing Comparative Oncology According to the National Cancer Institute, Roughly 6 Mill...
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Awa...
Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel
Jaguar Animal Health's Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet ...
Jaguar Health Reports First Quarter 2023 Financial Results
Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by whi...
REMINDER: Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Jaguar He...
Canalevia-CA1, Jaguar Animal Health's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" ...
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jagua...
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as...
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Hea...
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 2, 2023, the Company granted 100 restricted stock units...
Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi
Proof-of-concept studies of crofelemer in patients with short bowel syndrome (SBS) with intestinal failure or congenital diarrheal disorders planned for 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 1, 20...
U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care
91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia®-CA1 over time Canalevia-CA1, Jaguar Health's FDA ...
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Enrollment expected to complete in mid-Q2 2023 As of March 24, 2023, as previously announced, the Company's cash position was approximately $15.3 million SAN FRANCISCO, CA / ACCESSWIRE / April 11, 202...
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the Company's efforts to identify trading abnormalitie...
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA In December 2022, FDA increased the maximum number of dogs that can be treated annually with...
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million
Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Pre...
Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / ...
Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and its wholly owned subsidiary Napo Pharmaceuticals (Napo) today announced that Dr. Kel...
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
Click here to register for webcast Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / March 21, 2023 / ...
Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
The United Nations General Assembly's theme for the 2023 International Day of Forests is "Forests and Health" as Jaguar collaborates with communities in the Amazonia rainforest to ethically source the...
Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jag...
Jaguar Health to Present at BioTrinity 2023 Conference's R&D Spotlight on Rare Diseases
Presentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has re...
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
Crofelemer was previously granted Orphan Drug Designation by the FDA for short bowel syndrome SAN FRANCISCO, CA / ACCESSWIRE / February 28, 2023 / Jaguar Health (NASDAQ:JAGX) ("Jaguar" or the "Company...